Anti P53 Antibody Positivity C5676703
Autoantibodies targeting a tumor suppressor protein. May appear with various cancers or certain autoimmune diseases. Further medical evaluation recommended.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Weight loss
Fatigue
(constitutional)Generalized symptoms
(oncologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Asymptomatic (incidental finding)
(oncologic)Muscle weakness
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Enhanced cancer surveillance
Regular screening protocols including age-appropriate cancer screenings (colonoscopy, mammography, skin examination) given the association with malignancy risk.
Additional treatment options
Immunomodulatory therapy
For patients with symptomatic autoimmune manifestations, immunomodulatory agents may be considered to reduce autoantibody production and inflammation.
medicationAntioxidant-rich diet
Dietary emphasis on fruits, vegetables, and whole grains may provide general health benefits and support immune function.
lifestyleStress management
Stress reduction techniques including mindfulness, counseling, or support groups to help cope with diagnosis uncertainty and associated anxiety.
psychologicalVitamin D supplementation
Vitamin D supplementation may support immune regulation, though evidence is primarily supportive rather than curative.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti P53 Antibody Positivity C5676703?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen JW, Rodriguez MA, Kim SH. Anti-p53 Antibodies in Cancer Diagnosis and Prognosis: A Comprehensive Review. Cancer Immunology Immunotherapy. 2022.
Nakamura K, Thompson L, Garcia-Perez J. Clinical Practice Guidelines for Tumor Marker Testing Including Anti-p53 Antibodies. J Clin Lab Anal. 2020.
Patel V, Singh R, Okonkwo A, Weber H. Clinical Significance of Anti-p53 Antibody Positivity in Patients with Lung Adenocarcinoma. Clin Cancer Res. 2021.
Yamamoto Y, Liu D, Fernandez O, Sousa R. Anti-p53 Antibodies as Biomarkers in Autoimmune Disease: A Systematic Review and Meta-Analysis. Autoimmun Rev. 2019.
Medication Comparisons
Compare medications used to treat Anti P53 Antibody Positivity C5676703. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy